Earnings ·
Freenome reports Q3 revenue of $183.5M and GAAP net income of $60.1M
FRNMFreenome, Inc.
Freenome reported third-quarter 2026 total revenue of $183.5 million, a significant increase from $1.0 million in the prior-year period, driven primarily by a $180.0 million milestone payment under its collaboration and license agreement following FDA approval of SimpleScreen CRC for colorectal cancer screening. The company posted GAAP net income of $60.1 million compared to a net loss of $64.5 million in Q3 2025, with adjusted EBITDA turning positive at $117.9 million from negative $56.3 million. Freenome also provided full-year 2026 revenue guidance of $192 million to $194 million and reported cash, cash equivalents, and marketable securities totaling $430.0 million as of September 30, 2026. The company is a personalized cancer detection firm using an AI-driven multiomics platform to develop blood-based screening tests.